argenx SE
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ARGNF | ROIV | 9995.HK | 095700.KQ | 6IB.F | 688520.SS | |
|---|---|---|---|---|---|---|
| Market cap | 56.62B | 27.61B | 40.23B | 94.14B | 17.27B | 15.35B |
| P/E (TTM) | 31.2 | — | 6.1 | — | 123.8 | — |
| Forward P/E | — | -27.5 | 46.7 | — | — | 21.9 |
| Price/book | 6.7 | 6.5 | 3.8 | — | 6.2 | -22.6 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +7.18% | +85.85% | −19.94% | −60.56% | −1.76% | −37.00% |
| Today | 0.00% | +6.08% | +1.49% | +0.73% | +3.42% | +1.02% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All ARGNF news ›Analysts Have Conflicting Sentiments on These Healthcare Companies: Molina Healthcare (MOH), Quest Diagnostics (DGX) and Argenx Se (ARGX)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Molina Healthcare (MOH), Quest Diagnostics (DGX) and Argenx Se (ARGX). In a report released today, Andrew Mok CFA from Barclays maintained a…
Zacks Investment Ideas feature highlights: Cummins, Argenx and PACCAR
Chicago, IL – October 16, 2026– Today, Zacks Investment Ideas feature highlights Cummins CMI, Argenx ARGX and PACCAR PCAR. AI stocks sold off Wednesday and in early morning trading Thursday as investors raced to protect profits. That said,…
argenx's Forte acquisition delivers coeliac trial win
argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2 billion acquisition of Forte Biosciences, will move into phase 3 development for coeliac disease after showing efficacy in a mid-stage trial. There are no FDA-approved…
argenx Q3 2026: $1.72B Revenue and Five 2027 Launches Ahead
As seen on the 24/7 Wall St. homepage on October 22, 2026. As many as five new launches are lined up for 2027, spanning pediatric gMG, ocular MG, necrotizing myopathy, the autoinjector and empasiprubart in MMN, on the back of VYVGART…
argenx Reports Third Quarter 2026 Financial Results and Provides Business Update
Continued strong VYVGART performance drives $1.7 billion in global product net sales, representing 54% year-over-year growth and 13% quarter-over-quarter growth sBLA for VYVGART Hytrulo in IMNM on track for submission by year-end; pursuing…
Argenx outlines 2026 OpEx at ~$4B as it plans up to 5 U.S. launches in 2027
argenx Q3 2026 earnings: VYVGART sales hit $1.7B, 2027 launches loom, but DM and Sjogren risks remain. Earnings Call Insights: argenx (ARGX) Q3 2026 - Karen Massey (CEO & Executive Director) said, "Nearly 5 years into launch, we're still…
argenx (ARGX) Q3 2026 Earnings Call Transcript
Operator: Good morning. My name is Ryan, and I will be your conference operator today. I would like to welcome everyone to the call. [Operator Instructions] Thank you. I'd like to introduce Beth DelGiacco, Vice President of Corporate…
More from 1 other outlet
Argenx Slumps On Mixed Third Quarter, Surprise Vyvgart Testing Plans
Allison Gatlin covers biotechnology, pharmaceuticals and medical technology. She also oversees coverage of top-performing companies for Investor's Business Daily's The New America page. Allison has worked for Investor's Business Daily…
Argenx says Vyvgart sales rose 54% in third quarter
Sales of Vyvgart, a prescription drug used to treat adults with generalized myasthenia gravis, an autoimmune disease that causes muscle weakness, were $1.7 billion in the third quarter, up from $1.13 billion a year ago. • Operating profit…
argenx Q3 revenue and profit rises
argenx (ARGX) Q3 earnings: EPS $7.80, VYVGART sales up 54% to $1.7B, and 2026 expense outlook near $4B. - argenx SE press release (ARGX): Q3 EPS $7.80 diluted, compared with $5.18 a year earlier. - Outlook: Combined R&D and SG&A expenses…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- theglobeandmail.com9
- seekingalpha.com5
- stocktitan.net5
- statnews.com3
- tradingview.com3
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 56 articles, not a forecast.